In terms of clinical relevance, future studies should investigate the potential of KCNJ2 as a prognostic biomarker for ccRCC by assessing its performance in predicting patient outcomes in larger, independent cohorts. This evidence concerns the gene KCNJ2 and nonpapillary renal cell carcinoma.